Triptolide attenuates irritable bowel syndrome via inhibiting ODC1

BACKGROUND: Irritable bowel syndrome (IBS) is a chronic disorder of the gut-brain axis with significant morbidity. Triptolide, an active compound extracted from Tripterygium wilfordii Hook F (TwHF), has been widely used as a major medicinal herb in the treatment of inflammatory disease. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ning, Zhu, Liuyan, Zhang, Xueliang, Huang, Chengbin, Xiang, Wenjun, Huang, Bingwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258977/
https://www.ncbi.nlm.nih.gov/pubmed/37308808
http://dx.doi.org/10.1186/s12876-023-02847-8
_version_ 1785057570827796480
author Zhu, Ning
Zhu, Liuyan
Zhang, Xueliang
Huang, Chengbin
Xiang, Wenjun
Huang, Bingwu
author_facet Zhu, Ning
Zhu, Liuyan
Zhang, Xueliang
Huang, Chengbin
Xiang, Wenjun
Huang, Bingwu
author_sort Zhu, Ning
collection PubMed
description BACKGROUND: Irritable bowel syndrome (IBS) is a chronic disorder of the gut-brain axis with significant morbidity. Triptolide, an active compound extracted from Tripterygium wilfordii Hook F (TwHF), has been widely used as a major medicinal herb in the treatment of inflammatory disease. METHODS: The chronic-acute combined stress (CAS) stimulation was used to establish IBS rat model. The model rats were then gavaged with triptolide. Forced swimming, marble-burying, fecal weight and abdominal withdrawal reflex (AWR) score were recorded. Pathologic changes in the ileal and colonic tissues were validated by hematoxylin and eosin staining. The inflammatory cytokines and Ornithine Decarboxylase-1 (ODC1) in the ileal and colonic tissues were performed by ELISA and WB. RESULTS: Triptolide didn’t have antidepressant- and antianxiety- effects in rats caused by CAS, but decreased fecal weight and AWR score. In addition, Triptolide reduced the release of IL-1, IL-6, and TNF-α and the expression of ODC1 in the ileum and colon. CONCLUSION: The therapeutic efficacy of triptolide for IBS induced by CAS was revealed in this study, which may be related to the reduction of ODC1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02847-8.
format Online
Article
Text
id pubmed-10258977
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102589772023-06-13 Triptolide attenuates irritable bowel syndrome via inhibiting ODC1 Zhu, Ning Zhu, Liuyan Zhang, Xueliang Huang, Chengbin Xiang, Wenjun Huang, Bingwu BMC Gastroenterol Research BACKGROUND: Irritable bowel syndrome (IBS) is a chronic disorder of the gut-brain axis with significant morbidity. Triptolide, an active compound extracted from Tripterygium wilfordii Hook F (TwHF), has been widely used as a major medicinal herb in the treatment of inflammatory disease. METHODS: The chronic-acute combined stress (CAS) stimulation was used to establish IBS rat model. The model rats were then gavaged with triptolide. Forced swimming, marble-burying, fecal weight and abdominal withdrawal reflex (AWR) score were recorded. Pathologic changes in the ileal and colonic tissues were validated by hematoxylin and eosin staining. The inflammatory cytokines and Ornithine Decarboxylase-1 (ODC1) in the ileal and colonic tissues were performed by ELISA and WB. RESULTS: Triptolide didn’t have antidepressant- and antianxiety- effects in rats caused by CAS, but decreased fecal weight and AWR score. In addition, Triptolide reduced the release of IL-1, IL-6, and TNF-α and the expression of ODC1 in the ileum and colon. CONCLUSION: The therapeutic efficacy of triptolide for IBS induced by CAS was revealed in this study, which may be related to the reduction of ODC1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02847-8. BioMed Central 2023-06-12 /pmc/articles/PMC10258977/ /pubmed/37308808 http://dx.doi.org/10.1186/s12876-023-02847-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhu, Ning
Zhu, Liuyan
Zhang, Xueliang
Huang, Chengbin
Xiang, Wenjun
Huang, Bingwu
Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title_full Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title_fullStr Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title_full_unstemmed Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title_short Triptolide attenuates irritable bowel syndrome via inhibiting ODC1
title_sort triptolide attenuates irritable bowel syndrome via inhibiting odc1
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258977/
https://www.ncbi.nlm.nih.gov/pubmed/37308808
http://dx.doi.org/10.1186/s12876-023-02847-8
work_keys_str_mv AT zhuning triptolideattenuatesirritablebowelsyndromeviainhibitingodc1
AT zhuliuyan triptolideattenuatesirritablebowelsyndromeviainhibitingodc1
AT zhangxueliang triptolideattenuatesirritablebowelsyndromeviainhibitingodc1
AT huangchengbin triptolideattenuatesirritablebowelsyndromeviainhibitingodc1
AT xiangwenjun triptolideattenuatesirritablebowelsyndromeviainhibitingodc1
AT huangbingwu triptolideattenuatesirritablebowelsyndromeviainhibitingodc1

Ejemplares similares